(UroToday.com) In the Presidential Symposium 2 of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer, Dr. Karim Fizazi presented the results of PEACE-1 assessing the role of abiraterone acetate plus prednisone in men with de novo metastatic castration-sensitive prostate cancer (mCSPC).